Science ❯ Medical Research ❯ Clinical Trials ❯ Oncology

Phase 1/2 Trials for HLD-0915

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

The deal would bring Halda’s RIPTAC technology plus prostate cancer pill HLD-0915 under J&J pending antitrust clearance.